Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

Zivo Bioscience Inc.

ZIVO
$4.06 (+ $0.00 + 0.00%)
Last updated: Previous Close (2026-05-20)
ZIVO Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS98978N2009
Market Price4.06
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPSN/A
Market Cap$39.9M
Book Value-0.86
Price to Book-11.946
Beta0.57
52w High19.65
52w Low1.1
Next Earnings DateN/A
About the Company
Zivo Bioscience Inc. is a research and development company specializing in biotechnology, with a focus on leveraging proprietary algal and bacterial strains to create innovative nutritional compounds and bioactive molecules. The company's core operations center around the study, development, and commercialization of naturally derived ingredients targeting both human and animal health. Zivo Bioscience actively develops and licenses intellectual property, including unique algae cultures, extracts, and patented or patent-pending product concepts. Its primary fields of application include human dietary supplements, nutraceuticals, food ingredients, and animal feed additives, with projects addressing areas such as poultry gut health, bovine mastitis, canine joint health, and human immune modulation. Operating across both the biotech and agtech sectors, Zivo’s business model is heavily based on licensing its technology and selling specialized bioactive compounds to manufacturers in the nutrition, supplement, and medical food industries, emphasizing the growing market demand for natural, functional ingredients.
Price History
Latest News for ZIVO
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
TROY, Mich., September 10, 2025--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne.
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO’s Immune-Enhancing Compounds in Poultry
TROY, Mich., June 20, 2025--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, announces it has entered into a relationship with one of the world’s leading animal health companies to advance ZIVO’s novel immune-boosting compounds for use in multiple poultry market segments. The collaboration is expected to expand over time to address significant unmet needs in other live
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
TROY, Mich., May 06, 2025--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO’s proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among po